ABVC - ABVC BioPharma Inc. Debt to Book Capitalization Ratio

Graphic logo of ABVC BioPharma Inc. (ABVC)

ABVC BioPharma (ABVC) total debt-to-equity ratio demonstrates volatility in asset structure, with the metric reaching 0.26. This trend reflects bets on plant-based treatments for depression and ADHD. Independent researchers with transparent career tracks are driving this development. Meanwhile, modern extraction capacities consistently ensure the production of drugs for ongoing clinical trials.

ABVC (ABVC BioPharma, Inc) Debt to Book Value history from 07/04/2022 to 10/26/2026
Core merchandise of ABVC BioPharma Inc

Capital serves as a filter separating the fundamental value of a business from market speculation. The ultra-lean model of ABVC BioPharma, utilizing outsourcing via CROs, minimizes capital expenditures on infrastructure. This chart of the company's debt relative to its book capitalization measures the assets' dependence on borrowed funds. A decrease in this ratio confirms the strengthening of the financial base. Low debt leverage guarantees the company's resilience to external shocks.

Competitors of ABVC BioPharma

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio tonixpharma.com (TNXP)|Debts to Book Capitalization SXTC (China SXT Pharmaceuticals, Inc.)|Debts to Book Capitalization Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Debts to Book Capitalization|Invizyne (EXOZ) - Debt to Book Capitalization Ratio|oramed.com (ORMP) - Debt to Book Value|Entera Bio (ENTX) - Debt to Book Capitalization Ratio|Debts to Book Capitalization HYFT|Debt to Book Value Cumberland Pharmaceuticals Inc (CPIX)|Quantum BioPharma Limited (QNTM) - Debt to Book Value|Debt to Net Assets Ratio FibroGen Corporation (FGEN)|Debts to Book Capitalization Telomir Pharmaceuticals TELO|Debt to Book Capitalization Ratio Rani Therapeutics Holdings RANI|Debts to Book Capitalization SNYR (Synergy CHC Corporation)|RLYB: Debts to Net Assets|Debt to Book Capitalization Ratio LEXX|PULM (Pulmatrix Corporation) - Debts to Book Value|Debt to Book Capitalization Ratio Pheton Holdings Limited PTHL|Debts to Book Capitalization Ratio Aptorum|Lyra Therapeutics (LYRA) - Debts to Book Capitalization|Debt to Net Assets Ratio Impact BioMedical, Inc. (IBO)|Debts to Book Capitalization TNFA (TNF Pharmaceuticals, Inc.)|cbdMD Inc. - Debts to Book Capitalization|Debt to Book Capitalization Ratio PainReform Ltd. (PRFX)|CYTO: Debt to Net Assets Ratio|LIPO (Lipella Pharmaceuticals, Inc.) - Debt to Book Capitalization Ratio|OptiNose Inc (OPTN) - Debt to Book Value|PIRS (Pieris) - Debts to Book Capitalization|Debts to Book Capitalization Procaps Group Corp|Debts to Book Capitalization PTPI|Debts to Book Capitalization qlsyy.net (QLI)|Debts to Book Capitalization ACELYRIN SLRN|TFFP - Debt to Book Capitalization Ratio